ZA200209902B - New use of angiotensin II antagonists. - Google Patents
New use of angiotensin II antagonists. Download PDFInfo
- Publication number
- ZA200209902B ZA200209902B ZA200209902A ZA200209902A ZA200209902B ZA 200209902 B ZA200209902 B ZA 200209902B ZA 200209902 A ZA200209902 A ZA 200209902A ZA 200209902 A ZA200209902 A ZA 200209902A ZA 200209902 B ZA200209902 B ZA 200209902B
- Authority
- ZA
- South Africa
- Prior art keywords
- substance
- composition
- treatment
- angiotensin
- candesartan
- Prior art date
Links
- 229940123413 Angiotensin II antagonist Drugs 0.000 title description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title description 2
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 claims description 43
- 206010027599 migraine Diseases 0.000 claims description 43
- 208000019695 Migraine disease Diseases 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 37
- 208000001407 Vascular Headaches Diseases 0.000 claims description 31
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 25
- 229960004349 candesartan cilexetil Drugs 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 13
- 229960000932 candesartan Drugs 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 230000000069 prophylactic effect Effects 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 description 24
- 231100000869 headache Toxicity 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000006561 Cluster Headache Diseases 0.000 description 5
- 229940058087 atacand Drugs 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 102000005862 Angiotensin II Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 3
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010034960 Photophobia Diseases 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 208000018912 cluster headache syndrome Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960002198 irbesartan Drugs 0.000 description 3
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
- 206010016059 Facial pain Diseases 0.000 description 2
- 206010036313 Post-traumatic headache Diseases 0.000 description 2
- 206010043269 Tension headache Diseases 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000012790 cranial neuralgia Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000252151 Amiidae Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000027109 Headache disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 206010054956 Phonophobia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- HTQMVQVXFRQIKW-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HTQMVQVXFRQIKW-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950006523 cilexetil Drugs 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- VTDCYOLLYVAJSY-UHFFFAOYSA-N cyclohexyl propan-2-yl carbonate Chemical compound CC(C)OC(=O)OC1CCCCC1 VTDCYOLLYVAJSY-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001994 temporal artery Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Mattresses And Other Support Structures For Chairs And Beds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0002353A SE0002353D0 (sv) | 2000-06-22 | 2000-06-22 | New use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200209902B true ZA200209902B (en) | 2004-03-05 |
Family
ID=20280208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200209902A ZA200209902B (en) | 2000-06-22 | 2002-12-05 | New use of angiotensin II antagonists. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7872035B2 (zh) |
| EP (2) | EP1307192B1 (zh) |
| JP (1) | JP2003535897A (zh) |
| KR (1) | KR100692235B1 (zh) |
| CN (2) | CN1250218C (zh) |
| AT (1) | ATE318597T1 (zh) |
| AU (2) | AU2001274765B2 (zh) |
| BR (1) | BR0111900A (zh) |
| CA (1) | CA2411553A1 (zh) |
| DE (1) | DE60117541T2 (zh) |
| DK (1) | DK1307192T3 (zh) |
| ES (1) | ES2257416T3 (zh) |
| HK (1) | HK1053609A1 (zh) |
| IL (2) | IL153158A0 (zh) |
| MX (1) | MXPA02012574A (zh) |
| NO (1) | NO330300B1 (zh) |
| NZ (1) | NZ523048A (zh) |
| PT (1) | PT1307192E (zh) |
| SE (1) | SE0002353D0 (zh) |
| WO (1) | WO2001097807A1 (zh) |
| ZA (1) | ZA200209902B (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1356815A4 (en) * | 2001-01-29 | 2007-03-07 | Takeda Pharmaceutical | ANALGESIC AND ANTI-INFLAMMATORY DRUGS |
| US20050065094A1 (en) * | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| FR2892803B1 (fr) | 2005-10-28 | 2008-04-04 | Valeo Systemes Thermiques | Boite collectrice pour echangeur de chaleur, notamment pour evaporateur de climatisation, echangeur comportant une telle boite |
| JP5468420B2 (ja) * | 2010-03-04 | 2014-04-09 | 株式会社マキタ | 手持ち式切断工具 |
| WO2012135597A2 (en) * | 2011-03-30 | 2012-10-04 | The Johns Hopkins University | Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair |
| KR20130074808A (ko) | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
| TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
| US5241009A (en) | 1990-05-07 | 1993-08-31 | Kimberly-Clark Corporation | Polymeric composition containing carboxy nueutralized with lithium or potassium |
| CA2041763A1 (en) * | 1990-05-11 | 1991-11-12 | Sheih-Shung T. Chen | Microbial transformation process for antihypertensive products |
| US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
| US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5214153A (en) | 1992-04-23 | 1993-05-25 | Merck & Co., Inc. | Actinoplanes transformation process anti-hypertensive compound and method of use thereas |
-
2000
- 2000-06-22 SE SE0002353A patent/SE0002353D0/xx unknown
-
2001
- 2001-06-15 EP EP01941408A patent/EP1307192B1/en not_active Expired - Lifetime
- 2001-06-15 JP JP2002503291A patent/JP2003535897A/ja active Pending
- 2001-06-15 CN CNB018142788A patent/CN1250218C/zh not_active Expired - Fee Related
- 2001-06-15 AT AT01941408T patent/ATE318597T1/de active
- 2001-06-15 DK DK01941408T patent/DK1307192T3/da active
- 2001-06-15 AU AU2001274765A patent/AU2001274765B2/en not_active Ceased
- 2001-06-15 US US10/311,760 patent/US7872035B2/en not_active Expired - Fee Related
- 2001-06-15 PT PT01941408T patent/PT1307192E/pt unknown
- 2001-06-15 NZ NZ523048A patent/NZ523048A/en not_active IP Right Cessation
- 2001-06-15 ES ES01941408T patent/ES2257416T3/es not_active Expired - Lifetime
- 2001-06-15 BR BR0111900-1A patent/BR0111900A/pt not_active IP Right Cessation
- 2001-06-15 EP EP05028367A patent/EP1656940A1/en not_active Withdrawn
- 2001-06-15 WO PCT/SE2001/001379 patent/WO2001097807A1/en active IP Right Grant
- 2001-06-15 AU AU7476501A patent/AU7476501A/xx active Pending
- 2001-06-15 IL IL15315801A patent/IL153158A0/xx not_active IP Right Cessation
- 2001-06-15 DE DE60117541T patent/DE60117541T2/de not_active Expired - Lifetime
- 2001-06-15 MX MXPA02012574A patent/MXPA02012574A/es active IP Right Grant
- 2001-06-15 KR KR1020027017396A patent/KR100692235B1/ko not_active IP Right Cessation
- 2001-06-15 CA CA002411553A patent/CA2411553A1/en not_active Abandoned
- 2001-06-15 CN CNA2006100088164A patent/CN1846697A/zh active Pending
-
2002
- 2002-11-28 IL IL153158A patent/IL153158A/en unknown
- 2002-12-05 ZA ZA200209902A patent/ZA200209902B/en unknown
- 2002-12-18 NO NO20026085A patent/NO330300B1/no not_active IP Right Cessation
-
2003
- 2003-08-19 HK HK03105920A patent/HK1053609A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1053609A1 (en) | 2003-10-31 |
| PT1307192E (pt) | 2006-06-30 |
| EP1307192B1 (en) | 2006-03-01 |
| SE0002353D0 (sv) | 2000-06-22 |
| DK1307192T3 (da) | 2006-06-12 |
| CN1447693A (zh) | 2003-10-08 |
| NZ523048A (en) | 2004-09-24 |
| DE60117541T2 (de) | 2006-09-14 |
| WO2001097807A1 (en) | 2001-12-27 |
| NO20026085D0 (no) | 2002-12-18 |
| EP1656940A1 (en) | 2006-05-17 |
| IL153158A0 (en) | 2003-06-24 |
| CN1250218C (zh) | 2006-04-12 |
| AU2001274765B2 (en) | 2005-08-18 |
| AU7476501A (en) | 2002-01-02 |
| IL153158A (en) | 2008-03-20 |
| DE60117541D1 (de) | 2006-04-27 |
| NO20026085L (no) | 2002-12-18 |
| EP1307192A1 (en) | 2003-05-07 |
| NO330300B1 (no) | 2011-03-28 |
| KR20030019444A (ko) | 2003-03-06 |
| US20040092563A1 (en) | 2004-05-13 |
| CN1846697A (zh) | 2006-10-18 |
| ATE318597T1 (de) | 2006-03-15 |
| BR0111900A (pt) | 2003-05-13 |
| US7872035B2 (en) | 2011-01-18 |
| JP2003535897A (ja) | 2003-12-02 |
| ES2257416T3 (es) | 2006-08-01 |
| MXPA02012574A (es) | 2003-04-10 |
| CA2411553A1 (en) | 2001-12-27 |
| KR100692235B1 (ko) | 2007-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL153233A (en) | Extruded rubber structures for reinforcing internal spring assemblies and mattresses | |
| CA2260943C (en) | Formulation of 5-ht agonists | |
| US20040029941A1 (en) | Zonisamide use in obesity and eating disorders | |
| JP2002541097A (ja) | 線維筋痛症及び関連症状の治療におけるフルピルチン | |
| JPS61277620A (ja) | 排尿困難治療剤 | |
| JP2022507533A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| AU2001274765B2 (en) | New use of angiotensin II antagonists | |
| AU2001274765A1 (en) | New use of angiotensin II antagonists | |
| US6486188B1 (en) | Method of treatment for cardiovascular complications | |
| JP2005306882A (ja) | 感情的不安定の治療のための医薬の製造に有用な組成物 | |
| RU2369393C2 (ru) | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна | |
| JP2005132799A (ja) | 本態性振戦の予防・治療剤 | |
| AU2005234678A1 (en) | New use of angiotensin II antagonists | |
| US20050043407A1 (en) | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | |
| SK19252000A3 (sk) | Liečivo proti pľúcnej hypertenzii | |
| EP1180032A2 (en) | Use of nicorandil in treatment of sexual dysfunctions or for enhancement of sexual functions | |
| CN112512526B (zh) | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 | |
| Krogh et al. | Minor tranquillizers in somatic disorders. | |
| JP2024505246A (ja) | 神経変性認知障害を治療するための、コリンエステラーゼ阻害薬と四級アンモニウム抗ムスカリン剤との固定用量配合剤 | |
| AU2022294728A1 (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| WO2005027832A2 (en) | Edta containing compositions and uses thereof | |
| Trounce | Drugs in Current Use | |
| US20080176951A1 (en) | Methods of treating gastrointestinary and genitourinary pain disorders | |
| Vials | lSOPT1N “lv | |
| JP2005255695A (ja) | 慢性疼痛の治療のための医薬の製造に有用な組成物 |